朱素杰,女,1987年出生,博士,特聘教授。
2018年毕业于北京大学,获生物物理学博士学位。2018年9月进入青岛大学转化医学研究院工作,入选青岛大学第三层次特聘教授。
主要从事与肿瘤相关的各种激酶(EGFR、ALK等)致癌突变及耐药性突变的结构生物学研究,揭示耐药性突变的耐药机理,并基于小分子抑制剂与靶蛋白的复合物结构研究开发新一代靶向抑制剂。研究领域包括基于结构药理学的第四代EGFR靶向抑制剂的研发、第三代ALK靶向抑制剂的研发及免疫治疗相关靶点小分子抑制剂的筛选与优化、基于多组学交叉学科的抗肿瘤新靶点的挖掘及相对应靶向药物的筛选与设计。
联系方式:15652661318,zhusujie@qdu.edu.cn
课题组欢迎来自材料、化学、计算、生物、医学等不同领域的本科、硕士研究生、博士研究生和博士后的加入。
发表论文:(#第一作者,*通讯作者)
1. Huang, L., Zhu, J., Kong, W., Li, P., and Zhu, S*. (2021). Expression and Prognostic Characteristics of m6A RNA Methylation Regulators in Colon Cancer. Int J Mol Sci 22. (IF:5.923)
2. Yan, X.E., Ayaz, P., Zhu, S.J.#, Zhao, P., Liang, L., Zhang, C.H., Wu, Y.C., Li, J.L., Choi, H.G., Huang, X., et al. (2020). Structural Basis of AZD9291 Selectivity for EGFR T790M. J Med Chem 63, 8502-8511. (IF:7.446)
3. Shen, J., Zhang, T., Zhu, S.J.#, Sun, M., Tong, L., Lai, M., Zhang, R., Xu, W., Wu, R., Ding, J., et al. (2019). Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFR(L858R/T790M/C797S)). J Med Chem 62, 7302-7308. (IF:7.446)
4. Lu, X., Zhang, T., Zhu, S.J.#, Xun, Q., Tong, L., Hu, X., Li, Y., Chan, S., Su, Y., Sun, Y., et al. (2018). Discovery of JND3229 as a New EGFR(C797S) Mutant Inhibitor with In Vivo Monodrug Efficacy. ACS Med Chem Lett 9, 1123-1127. (IF:4.345)
5. Zhu, S.J.#, Zhao, P., Yang, J., Ma, R., Yan, X.E., Yang, S.Y., Yang, J.W., and Yun, C.H. (2018). Structural insights into drug development strategy targeting EGFR T790M/C797S. Oncotarget 9, 13652-13665. (IF2015=5.168)
6. Yan, X.E., Zhu, S.J.#, Liang, L., Zhao, P., Choi, H.G., and Yun, C.H. (2017). Structural basis of mutant-selectivity and drug-resistance related to CO-1686. Oncotarget 8, 53508-53517. (IF2015=5.168)
7. Anastasi, S., Zhu, S.J.#, Ballaro, C., Manca, S., Lamberti, D., Wang, L.J., Alema, S., Yun, C.H., and Segatto, O. (2016). Lack of Evidence that CYTH2/ARNO Functions as a Direct Intracellular EGFR Activator. Cell 165, 1031-1034. (IF:41.582)